top of page
The Professional Network for Healthcare Experts
IASO Bio acquires Singapore’s MediSix Therapeutics to expand global cell therapy platform
The acquisition adds MediSix’s proprietary T-cell engineering technologies and pipeline to IASO Bio’s integrated cell therapy capabilities while strengthening its presence in Singapore and international markets.
nuaxia
11 hours ago3 min read
FDA Approves First Regulatory T-Cell Therapy for Chronic GVHD Prevention
The FDA has approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy to improve chronic graft-versus-host disease (GVHD)-free survival in adults with blood cancers
nuaxia
Jul 22 min read
bottom of page